Company Profile

Kephera Diagnostics LLC
Profile last edited on: 3/12/21      CAGE: 7RVB8      UEI: LJFNSE6NM648

Business Identifier: Diagnostics for emerging and neglected infectious diseases
Year Founded
2017
First Award
2017
Latest Award
2021
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1 Grant Street Suite 300
Framingham, MA 01702
   (617) 834-0950
   info@kepheradx.com
   www.kepheradx.com
Location: Single
Congr. District: 05
County: Middlesex

Public Profile

Kephera Diagnostics is organized around development of innovative technologies for diagnosis of infectious diseases with particular emphasis on emerging diseases of major public health significance worldwide. To that end, Kephera personnel are working on developiment of rapid tests for infectious diseases using novel immunochemistry in point-of-care format. Based on principles of particle interaction combined with a simple device, the firm's proprietary assay technology enable rapid detection of specific antibodies or antigens associated with the target pathogen. The broadly enabling technology is applicable to a wide range of disease targets and applications. Kephera’s expertise extends from antigen discovery using microarrays and peptide libraries to assay development, clinical studies and validation. Kephera is particularly focused on development of a test for Zika virus infection an effort structured around identification of Zika-specific and Dengue-specific epitopes within the viral genome, from which an immunoassay will be developed in convenient and cost-effective ELISA format, and ultimately translated to point-of-care format. To this end, the firm's personnel are collaborating with medical research institutes in the U.S. and in Latin America to analyze the immunological reactivities of patient sera from Zika and Dengue-endemic regions. Involving a variety of epitope mapping techniques, epitopes are selected based on ability to differentiate viral infections will then be expressed synthetically or as recombinant antigens for assay development. Other diseases of interest for study are Chagas Disease and Lyme Disease

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Key People / Management

  Andrew E Levin -- Founder, CEO and Chief Scientific Officer

  David Boyle -- Business Manager

  Leah Carlson -- Research Associate

  Cameron Friedman -- Research Assistant

  Vashti Irani -- Research Scientist, Infectious Diseases

  Nadya Karaseva -- Senior Scientist and R&D Project Manager

  Jeremy Schonhorn -- Director of Product Development

Company News

There are no news available.